CROSSJECT (ALCJ.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALCJ - FR0011716265 - Common Stock
ALCJ.PA Key Statistics, Chart & Performance
The current stock price of ALCJ.PA is 2.09 EUR. In the past month the price decreased by -20.23%. In the past year, price increased by 0.97%.
ALCJ.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1EL.MI | ESSILORLUXOTTICA | 41.48 | 132.00B | ||
| EL.PA | ESSILORLUXOTTICA | 41.16 | 130.98B | ||
| ESL.DE | ESSILORLUXOTTICA | 40.99 | 130.42B | ||
| GBT.PA | GUERBET | 22.03 | 169.88M | ||
| AFME.PA | AFFLUENT MEDICAL SA | N/A | 56.47M | ||
| SVS.MI | SVAS BIOSANA SPA | 6.72 | 47.82M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 38.44M |
Related stock screener links
About ALCJ.PA
Company Profile
Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 108 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Company Info
CROSSJECT
Parc Mazen-Sully, 6 Rue Pauline Kergomard
Dijon BOURGOGNE-FRANCHE-COMTE FR
Employees: 108
Phone: 33380549850
CROSSJECT / ALCJ.PA FAQ
What does ALCJ do?
Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 108 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
What is the stock price of CROSSJECT today?
The current stock price of ALCJ.PA is 2.09 EUR. The price increased by 1.95% in the last trading session.
Does ALCJ stock pay dividends?
ALCJ.PA does not pay a dividend.
How is the ChartMill rating for CROSSJECT?
ALCJ.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is CROSSJECT (ALCJ.PA) stock traded?
ALCJ.PA stock is listed on the Euronext Paris exchange.
What is the expected growth for ALCJ stock?
The Revenue of CROSSJECT (ALCJ.PA) is expected to grow by 428.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for CROSSJECT?
CROSSJECT (ALCJ.PA) will report earnings on 2026-03-25, after the market close.
ALCJ.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALCJ.PA. When comparing the yearly performance of all stocks, ALCJ.PA is one of the better performing stocks in the market, outperforming 79.29% of all stocks.
ALCJ.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA. ALCJ.PA may be in some trouble as it scores bad on both profitability and health.
ALCJ.PA Financial Highlights
Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 13.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.32% | ||
| ROE | -308.32% | ||
| Debt/Equity | 0.71 |
ALCJ.PA Forecast & Estimates
9 analysts have analysed ALCJ.PA and the average price target is 3.88 EUR. This implies a price increase of 85.45% is expected in the next year compared to the current price of 2.09.
For the next year, analysts expect an EPS growth of 135.12% and a revenue growth 428.6% for ALCJ.PA